InstitutionMD Anderson
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Narsinh KH, Perez E, Haddad AF, Young JS, Savastano L, Villanueva-Meyer JE, Winkler E, de Groot J. Strategies to Improve Drug Delivery Across the Blood-Brain Barrier for Glioblastoma. Curr Neurol Neurosci Rep. 2024 May; 24(5):123-139. PMID: 38578405.
      Citations:    Fields:    
    2. Carpentier A, Stupp R, Sonabend AM, Dufour H, Chinot O, Mathon B, Ducray F, Guyotat J, Baize N, Menei P, de Groot J, Weinberg JS, Liu BP, Guemas E, Desseaux C, Schmitt C, Bouchoux G, Canney M, Idbaih A. Repeated blood-brain barrier opening with a nine-emitter implantable ultrasound device in combination with carboplatin in recurrent glioblastoma: a phase I/II clinical trial. Nat Commun. 2024 Feb 23; 15(1):1650. PMID: 38396134; PMCID: PMC10891097.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    3. Myers AA, Tan WS, de Groot J, Westney OL, Kamat AM. 'Case of the Month' from The University of Texas MD Anderson Cancer Center, Houston, Texas, USA: ependymoma of the urinary bladder. BJU Int. 2024 Feb 20. PMID: 38379218.
      Citations:    Fields:    
    4. Arrillaga-Romany I, Gardner SL, Odia Y, Aguilera D, Allen JE, Batchelor T, Butowski N, Chen C, Cloughesy T, Cluster A, de Groot J, Dixit KS, Graber JJ, Haggiagi AM, Harrison RA, Kheradpour A, Kilburn L, Kurz SC, Lu G, MacDonald TJ, Mehta M, Melemed AS, Nghiemphu PL, Ramage SC, Shonka N, Sumrall A, Tarapore R, Taylor L, Umemura Y, Wen PY, Kilburn LB, Tarapore RS. ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma. J Clin Oncol. 2024 Feb 09; JCO2301134. PMID: 38335473.
      Citations: 1     Fields:    
    5. Albert NL, Galldiks N, Ellingson BM, van den Bent MJ, Chang SM, Cicone F, de Groot J, Koh ES, Law I, Le Rhun E, Mair MJ, Minniti G, Rud? R, Scott AM, Short SC, Smits M, Suchorska B, Tolboom N, Traub-Weidinger T, Tonn JC, Verger A, Weller M, Wen PY, Preusser M. PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group. Lancet Oncol. 2024 Jan; 25(1):e29-e41. PMID: 38181810.
      Citations: 2     Fields:    Translation:Humans
    6. Hadad S, Gupta R, Oberheim Bush NA, Taylor JW, Villanueva-Meyer JE, Young JS, Wu J, Ravindranathan A, Zhang Y, Warrier G, McCoy L, Shai A, Pekmezci M, Perry A, Bollen AW, Phillips JJ, Braunstein SE, Raleigh DR, Theodosopoulos P, Aghi MK, Chang EF, Hervey-Jumper SL, Costello JF, de Groot J, Butowski NA, Clarke JL, Chang SM, Berger MS, Molinaro AM, Solomon DA. "De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade. Acta Neuropathol. 2023 Dec 11; 147(1):3. PMID: 38079020; PMCID: PMC10713691.
      Citations:    Fields:    Translation:Humans
    7. Venneti S, Kawakibi AR, Ji S, Waszak SM, Sweha SR, Mota M, Pun M, Deogharkar A, Chung C, Tarapore RS, Ramage S, Chi A, Wen PY, Arrillaga-Romany I, Batchelor TT, Butowski NA, Sumrall A, Shonka N, Harrison RA, de Groot J, Mehta M, Hall MD, Daghistani D, Cloughesy TF, Ellingson BM, Beccaria K, Varlet P, Kim MM, Umemura Y, Garton H, Franson A, Schwartz J, Jain R, Kachman M, Baum H, Burant CF, Mottl SL, Cartaxo RT, John V, Messinger D, Qin T, Peterson E, Sajjakulnukit P, Ravi K, Waugh A, Walling D, Ding Y, Xia Z, Schwendeman A, Hawes D, Yang F, Judkins AR, Wahl D, Lyssiotis CA, de la Nava D, Alonso MM, Eze A, Spitzer J, Schmidt SV, Duchatel RJ, Dun MD, Cain JE, Jiang L, Stopka SA, Baquer G, Regan MS, Filbin MG, Agar NYR, Zhao L, Kumar-Sinha C, Mody R, Chinnaiyan A, Kurokawa R, Pratt D, Yadav VN, Grill J, Kline C, Mueller S, Resnick A, Nazarian J, Allen JE, Odia Y, Gardner SL, Koschmann C. Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways. Cancer Discov. 2023 11 01; 13(11):2370-2393. PMID: 37584601; PMCID: PMC10618742.
      Citations: 7     Fields:    Translation:Humans
    8. Khan S, Martinez-Ledesma E, Dong J, Mahalingam R, Park SY, Piao Y, Koul D, Balasubramaniyan V, de Groot JF, Yung WKA. Neuronal differentiation drives the antitumor activity of mitogen-activated protein kinase kinase (MEK) inhibition in glioblastoma. Neurooncol Adv. 2023 Jan-Dec; 5(1):vdad132. PMID: 38130900; PMCID: PMC10734674.
      Citations: 1     
    9. Singh K, Hotchkiss KM, Parney IF, De Groot J, Sahebjam S, Sanai N, Platten M, Galanis E, Lim M, Wen PY, Minniti G, Colman H, Cloughesy TF, Mehta MP, Geurts M, Arrillaga-Romany I, Desjardins A, Tanner K, Short S, Arons D, Duke E, Wick W, Bagley SJ, Ashley DM, Kumthekar P, Verhaak R, Chalmers AJ, Patel AP, Watts C, Fecci PE, Batchelor TT, Weller M, Vogelbaum MA, Preusser M, Berger MS, Khasraw M. Correcting the drug development paradigm for glioblastoma requires serial tissue sampling. Nat Med. 2023 Oct; 29(10):2402-2405. PMID: 37488293.
      Citations: 3     Fields:    Translation:Humans
    10. Wen PY, van den Bent M, Youssef G, Cloughesy TF, Ellingson BM, Weller M, Galanis E, Barboriak DP, de Groot J, Gilbert MR, Huang R, Lassman AB, Mehta M, Molinaro AM, Preusser M, Rahman R, Shankar LK, Stupp R, Villanueva-Meyer JE, Wick W, Macdonald DR, Reardon DA, Vogelbaum MA, Chang SM. RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. J Clin Oncol. 2023 Nov 20; 41(33):5187-5199. PMID: 37774317; PMCID: PMC10860967.
      Citations: 10     Fields:    Translation:Humans
    11. Sooreshjani M, Tripathi S, Dussold C, Najem H, de Groot J, Lukas RV, Heimberger AB. The Use of Targeted Cytokines as Cancer Therapeutics in Glioblastoma. Cancers (Basel). 2023 Jul 23; 15(14). PMID: 37509400; PMCID: PMC10378451.
    12. Mandel JJ, de Groot JF. External Control Arms and Data Analysis Methods in Nonrandomized Trial of Patients With Glioblastoma. JAMA Oncol. 2023 07 01; 9(7):1006. PMID: 37200018.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    13. van der Valk WH, van Beelen ESA, Steinhart MR, Nist-Lund C, Osorio D, de Groot JCMJ, Sun L, van Benthem PPG, Koehler KR, Locher H. A single-cell level comparison of human inner ear organoids with the human cochlea and vestibular organs. Cell Rep. 2023 06 27; 42(6):112623. PMID: 37289589; PMCID: PMC10592453.
      Citations: 1     Fields:    Translation:HumansCells
    14. van den Bent M, Ellingson BM, Wen PY, Chang SM, Vogelbaum MA, Li G, Li S, Kim J, Youssef G, Wick W, Lassman AB, Gilbert MR, de Groot JF, Weller M, Galanis E, Cloughesy TF. Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival. Neuro Oncol. 2023 06 02; 25(6):1017-1028. PMID: 36617262; PMCID: PMC10237425.
      Citations: 8     Fields:    Translation:Humans
    15. Gregory TA, Mastall M, Lin H, Hess KR, Yuan Y, Martin-Bejarano Garcia M, Fuller GN, Alfaro KD, Gule-Monroe MK, Huse JT, Khatua S, Rao G, Sandberg DI, Wefel JS, Yeboa DN, Paulino AC, McGovern SL, Zaky W, Mahajan A, Suki D, Weathers SP, Harrison RA, de Groot JF, Puduvalli VK, Penas-Prado M, Majd NK. Characterization of recurrence patterns and outcomes of medulloblastoma in adults: The University of Texas MD Anderson Cancer Center experience. Neurooncol Adv. 2023 Jan-Dec; 5(1):vdad032. PMID: 37114244; PMCID: PMC10129387.
    16. Gregory TA, Williford GL, Maronge JM, Alfaro K, Fuller GN, de Groot J, Puduvalli VK, Ballester LY, Majd NK. An expedited strategy for accurate and timely integrated molecular diagnosis of?gliomas. Neuro Oncol. 2023 04 06; 25(4):808-809. PMID: 36723868; PMCID: PMC10076931.
      Citations:    Fields:    Translation:Humans
    17. Rahman R, Polley MC, Alder L, Brastianos PK, Anders CK, Tawbi HA, Mehta M, Wen PY, Geyer S, de Groot J, Zadeh G, Piantadosi S, Galanis E, Khasraw M. Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference. Lancet Oncol. 2023 04; 24(4):e161-e171. PMID: 36990614; PMCID: PMC10401610.
      Citations: 1     Fields:    Translation:Humans
    18. Dasgupta P, Balasubramanyian V, de Groot JF, Majd NK. Preclinical Models of Low-Grade Gliomas. Cancers (Basel). 2023 Jan 18; 15(3). PMID: 36765553; PMCID: PMC9913857.
      Citations: 2     
    19. Rogers CL, Pugh SL, Vogelbaum MA, Perry A, Ashby LS, Modi JM, Alleman AM, Barani IJ, Braunstein S, Bovi JA, de Groot JF, Whitton AC, Lindhorst SM, Deb N, Shrieve DC, Shu HK, Bloom B, Machtay M, Mishra MV, Robinson CG, Won M, Mehta MP. Low-risk meningioma: Initial outcomes from NRG Oncology/RTOG 0539. Neuro Oncol. 2023 01 05; 25(1):137-145. PMID: 35657335; PMCID: PMC9825319.
      Citations:    Fields:    
    20. Upadhyay R, Khose S, Pokhylevych H, Paulino AC, McAleer MF, Ghia A, Li J, Yeboa DN, Loghin M, Harrison R, O'Brien B, Kamiya-Matsuoka C, De Groot J, Puduvalli VK, Tatsui C, Alvarez-Breckenridge C, Prabhu S, Rhines L, Zaky W, Lin F, Weinberg JS, Fuller G, Sandberg DI, Johnson JM, McGovern SL. Patterns of failure after radiation therapy in primary spinal high-grade gliomas: A single institutional analysis. Neurooncol Adv. 2022 Jan-Dec; 4(1):vdac129. PMID: 36128585; PMCID: PMC9476222.
    21. Lucas CG, Sloan EA, Gupta R, Wu J, Pratt D, Vasudevan HN, Ravindranathan A, Barreto J, Williams EA, Shai A, Whipple NS, Bruggers CS, Maher O, Nabors B, Rodriguez M, Samuel D, Brown M, Carmichael J, Lu R, Mirchia K, Sullivan DV, Pekmezci M, Tihan T, Bollen AW, Perry A, Banerjee A, Mueller S, Gupta N, Hervey-Jumper SL, Oberheim Bush NA, Daras M, Taylor JW, Butowski NA, de Groot J, Clarke JL, Raleigh DR, Costello JF, Phillips JJ, Reddy AT, Chang SM, Berger MS, Solomon DA. Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. Acta Neuropathol. 2022 10; 144(4):747-765. PMID: 35945463; PMCID: PMC9468105.
    22. Soffietti R, Bettegowda C, Mellinghoff IK, Warren KE, Ahluwalia MS, De Groot JF, Galanis E, Gilbert MR, Jaeckle KA, Le Rhun E, Thon N, Umemura Y, Weller M, van den Bent MJ, Vogelbaum MA, Chang SM, Wen PY, Rud? R, Seoane J. Liquid biopsy in gliomas: A RANO review and proposals for clinical applications. Neuro Oncol. 2022 06 01; 24(6):855-871. PMID: 34999836; PMCID: PMC9159432.
      Citations:    Fields:    Translation:HumansCells
    23. Dono A, Alfaro-Munoz K, Yan Y, Lopez-Garcia CA, Soomro Z, Williford G, Takayasu T, Robell L, Majd NK, de Groot J, Esquenazi Y, Kamiya-Matsuoka C, Ballester LY. Molecular, Histological, and Clinical Characteristics of Oligodendrogliomas: A Multi-Institutional Retrospective Study. Neurosurgery. 2022 05 01; 90(5):515-522. PMID: 35179134; PMCID: PMC9514747.
      Citations:    Fields:    Translation:Humans
    24. de Groot JF, Kim AH, Prabhu S, Rao G, Laxton AW, Fecci PE, O'Brien BJ, Sloan A, Chiang V, Tatter SB, Mohammadi AM, Placantonakis DG, Strowd RE, Chen C, Hadjipanayis C, Khasraw M, Sun D, Piccioni D, Sinicrope KD, Campian JL, Kurz SC, Williams B, Smith K, Tovar-Spinoza Z, Leuthardt EC. Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma. Neurooncol Adv. 2022 Jan-Dec; 4(1):vdac040. PMID: 35611270; PMCID: PMC9122789.
    25. Amer A, Khose S, Alhasan H, Pokhylevych H, Fuller G, Chasen N, de Groot J, Johnson JM. Clinical and survival characteristics of primary and secondary gliosarcoma patients. Clin Neurol Neurosurg. 2022 03; 214:107146. PMID: 35101778.
      Citations:    Fields:    Translation:Humans
    26. de Groot PM, Arevalo O, Shah K, Strange CD, Shroff GS, Ahuja J, Truong MT, de Groot JF, Vlahos I. Imaging Primer on Chimeric Antigen Receptor T-Cell Therapy for Radiologists. Radiographics. 2022 Jan-Feb; 42(1):176-194. PMID: 34990326.
      Citations:    Fields:    Translation:Humans
    27. Harrison RA, Ou A, Naqvi SMAA, Naqvi SM, Weathers SS, O'Brien BJ, de Groot JF, Bruera E. Aggressiveness of care at end of life in patients with high-grade glioma. Cancer Med. 2021 12; 10(23):8387-8394. PMID: 34755486; PMCID: PMC8633215.
      Citations: 2     Fields:    Translation:Humans
    28. Galanis E, Wen PY, de Groot JF, Weller M. Isocitrate Dehydrogenase Wild-type Glial Tumors, Including Glioblastoma. Hematol Oncol Clin North Am. 2022 02; 36(1):113-132. PMID: 34756799.
      Citations: 1     Fields:    Translation:Humans
    29. Khan S, Mahalingam R, Sen S, Martinez-Ledesma E, Khan A, Gandy K, Lang FF, Sulman EP, Alfaro-Munoz KD, Majd NK, Balasubramaniyan V, de Groot JF. Intrinsic Interferon Signaling Regulates the Cell Death and Mesenchymal Phenotype of Glioblastoma Stem Cells. Cancers (Basel). 2021 Oct 21; 13(21). PMID: 34771447; PMCID: PMC8582372.
      Citations: 1     
    30. Weathers SP, Rood-Breithaupt J, de Groot J, Thomas G, Manfrini M, Penas-Prado M, Puduvalli VK, Zwingelstein C, Yung WKA. Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab141. PMID: 34693288; PMCID: PMC8528265.
    31. Lee EQ, Selig W, Meehan C, Bacha J, Barone A, Bloomquist E, Chang SM, de Groot JF, Galanis E, Hassan I, Kalidas C, Khasraw M, Kvedar JC, Lassman AB, Puduvalli V, Sahebjam S, Schwamm LH, Tamir S, Welch M, Yung WKA, Zadeh G, Arons D, Wen PY. Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experience. Neuro Oncol. 2021 08 02; 23(8):1252-1260. PMID: 33822177; PMCID: PMC8083574.
      Citations: 1     Fields:    Translation:HumansCells
    32. Brown PD, Chung C, Liu DD, McAvoy S, Grosshans D, Al Feghali K, Mahajan A, Li J, McGovern SL, McAleer MF, Ghia AJ, Sulman EP, Penas-Prado M, de Groot JF, Heimberger AB, Wang J, Armstrong TS, Gilbert MR, Guha-Thakurta N, Wefel JS. A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma. Neuro Oncol. 2021 08 02; 23(8):1337-1347. PMID: 33647972; PMCID: PMC8328012.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    33. Barekatain Y, Ackroyd JJ, Yan VC, Khadka S, Wang L, Chen KC, Poral AH, Tran T, Georgiou DK, Arthur K, Lin YH, Satani N, Ballato ES, Behr EI, deCarvalho AC, Verhaak RGW, de Groot J, Huse JT, Asara JM, Kalluri R, Muller FL. Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine. Nat Commun. 2021 07 09; 12(1):4228. PMID: 34244484; PMCID: PMC8270912.
      Citations: 2     Fields:    Translation:HumansCells
    34. Ellingson BM, Patel K, Wang C, Raymond C, Brenner A, de Groot JF, Butowski NA, Zach L, Campian JL, Schlossman J, Rizvi S, Cohen YC, Lowenton-Spier N, Minei TR, Shmueli SF, Wen PY, Cloughesy TF. Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab082. PMID: 34377989; PMCID: PMC8350152.
      Citations: 1     
    35. Mandel JJ, Youssef M, Yust-Katz S, Patel AJ, Jalali A, Li Z, Wu J, Ludmir EB, de Groot JF. IDH mutation status and the development of venous thromboembolism in astrocytoma patients. J Neurol Sci. 2021 Aug 15; 427:117538. PMID: 34146775.
      Citations:    Fields:    Translation:Humans
    36. Al Feghali KA, Randall JW, Liu DD, Wefel JS, Brown PD, Grosshans DR, McAvoy SA, Farhat MA, Li J, McGovern SL, McAleer MF, Ghia AJ, Paulino AC, Sulman EP, Penas-Prado M, Wang J, de Groot J, Heimberger AB, Armstrong TS, Gilbert MR, Mahajan A, Guha-Thakurta N, Chung C. Phase II trial of proton therapy versus photon IMRT for GBM: secondary analysis comparison of progression-free survival between RANO versus clinical assessment. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab073. PMID: 34337411; PMCID: PMC8320688.
    37. Wu S, Li X, Gao F, de Groot JF, Koul D, Yung WKA. PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma. Neuro Oncol. 2021 06 01; 23(6):920-931. PMID: 33433610; PMCID: PMC8168825.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    38. Mohan R, Liu AY, Brown PD, Mahajan A, Dinh J, Chung C, McAvoy S, McAleer MF, Lin SH, Li J, Ghia AJ, Zhu C, Sulman EP, de Groot JF, Heimberger AB, McGovern SL, Grassberger C, Shih H, Ellsworth S, Grosshans DR. Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons. Neuro Oncol. 2021 02 25; 23(2):284-294. PMID: 32750703; PMCID: PMC7906048.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    39. Majd NK, Yap TA, Koul D, Balasubramaniyan V, Li X, Khan S, Gandy KS, Yung WKA, de Groot JF. The promise of DNA damage response inhibitors for the treatment of glioblastoma. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab015. PMID: 33738447; PMCID: PMC7954093.
      Citations: 3     
    40. Majd NK, Dasgupta PR, de Groot JF. Immunotherapy for Neuro-oncology. Adv Exp Med Biol. 2021; 1342:233-258. PMID: 34972967.
      Citations:    Fields:    Translation:Humans
    41. Harrison RA, Majd NK, Tummala S, de Groot JF. Neurologic Toxicities of Immunotherapy. Adv Exp Med Biol. 2021; 1342:417-429. PMID: 34972978.
      Citations:    Fields:    Translation:Humans
    42. Nayak L, Molinaro AM, Peters K, Clarke JL, Jordan JT, de Groot J, Nghiemphu L, Kaley T, Colman H, McCluskey C, Gaffey S, Smith TR, Cote DJ, Severgnini M, Yearley JH, Zhao Q, Blumenschein WM, Duda DG, Muzikansky A, Jain RK, Wen PY, Reardon DA. Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. Clin Cancer Res. 2021 02 15; 27(4):1048-1057. PMID: 33199490; PMCID: PMC8284901.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    43. Majd N, Yap TA, Yung WKA, de Groot J. The Promise of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Gliomas. J Immunother Precis Oncol. 2020 Nov; 3(4):157-164. PMID: 35665372; PMCID: PMC9165443.
    44. Park SY, Mittal S, Dong J, Jeong K, Martinez-Ledesma E, Piao Y, Khan S, Henry V, Verhaak RG, Majd N, Balasubramaniyan V, de Groot JF. Depletion of CLK2 sensitizes glioma stem-like cells to PI3K/mTOR and FGFR inhibitors. Am J Cancer Res. 2020; 10(11):3765-3783. PMID: 33294266; PMCID: PMC7716149.
      Citations: 3     
    45. Ferguson SD, Hodges TR, Majd NK, Alfaro-Munoz K, Al-Holou WN, Suki D, de Groot JF, Fuller GN, Xue L, Li M, Jacobs C, Rao G, Colen RR, Xiu J, Verhaak R, Spetzler D, Khasraw M, Sawaya R, Long JP, Heimberger AB. A validated integrated clinical and molecular glioblastoma long-term survival-predictive nomogram. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdaa146. PMID: 33426529; PMCID: PMC7780842.
      Citations: 1     
    46. Aaroe AE, Majd N, Weathers SP, de Groot JF. Potential neurologic and oncologic implications of the novel coronavirus. Neuro Oncol. 2020 07 07; 22(7):1050-1051. PMID: 32296828; PMCID: PMC7184395.
      Citations: 2     Fields:    Translation:HumansCellsPHPublic Health
    47. Barekatain Y, Yan VC, Arthur K, Ackroyd JJ, Khadka S, De Groot J, Huse JT, Muller FL. Robust detection of oncometabolic aberrations by 1H-13C heteronuclear single quantum correlation in intact biological specimens. Commun Biol. 2020 06 25; 3(1):328. PMID: 32587392; PMCID: PMC7316726.
      Citations:    Translation:HumansAnimalsCells
    48. Harrison RA, Tummala S, de Groot J. Neurologic Toxicities of Cancer Immunotherapies: a Review. Curr Neurol Neurosci Rep. 2020 06 08; 20(7):27. PMID: 32514633.
      Citations: 3     Fields:    Translation:Humans
    49. Berkman AM, Livingston JA, Merriman K, Hildebrandt M, Wang J, Dibaj S, McQuade J, You N, Ying A, Barcenas C, Bodurka D, DePombo A, Lee HJ, de Groot J, Roth M. Long-term survival among 5-year survivors of adolescent and young adult cancer. Cancer. 2020 08 15; 126(16):3708-3718. PMID: 32484922; PMCID: PMC7381371.
      Citations: 10     Fields:    Translation:Humans
    50. Cloughesy TF, Brenner A, de Groot JF, Butowski NA, Zach L, Campian JL, Ellingson BM, Freedman LS, Cohen YC, Lowenton-Spier N, Rachmilewitz Minei T, Fain Shmueli S, GLOBE Study Investigators, Wen PY. A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE). Neuro Oncol. 2020 05 15; 22(5):705-717. PMID: 31844890; PMCID: PMC7229248.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    51. Nam JY, Gilbert A, Cachia D, Mandel J, Fuller GN, Penas-Prado M, de Groot J, Kamiya-Matsuoka C. Pineal parenchymal tumor of intermediate differentiation: a single-institution experience. Neurooncol Pract. 2020 Dec; 7(6):613-619. PMID: 33312675; PMCID: PMC7716182.
      Citations: 3     
    52. Weathers SP, Penas-Prado M, Pei BL, Ling X, Kassab C, Banerjee P, Bdiwi M, Shaim H, Alsuliman A, Shanley M, de Groot JF, O'Brien BJ, Harrison R, Majd N, Kamiya-Matsuoka C, Fuller GN, Huse JT, Chi L, Rao G, Weinberg JS, Lang FF, Sawaya R, Shpall EJ, Rezvani K, Heimberger AB. Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial. Clin Cancer Res. 2020 07 15; 26(14):3565-3577. PMID: 32299815; PMCID: PMC9347965.
      Citations: 15     Fields:    Translation:HumansCellsCTClinical Trials
    53. Patel RR, Verma V, Miller AB, Lin TA, Jethanandani A, Espinoza AF, Mainwaring W, Augustyn A, Fuller CD, Sulman EP, Yeboa DN, Chung CC, McAleer MF, Li J, Yoshor D, de Groot JF, Mandel JJ, Ludmir EB. Exclusion of patients with brain metastases from cancer clinical trials. Neuro Oncol. 2020 04 15; 22(4):577-579. PMID: 31900480; PMCID: PMC7158639.
      Citations: 3     Fields:    Translation:Humans
    54. de Groot J, Penas-Prado M, Alfaro-Munoz K, Hunter K, Pei BL, O'Brien B, Weathers SP, Loghin M, Kamiya Matsouka C, Yung WKA, Mandel J, Wu J, Yuan Y, Zhou S, Fuller GN, Huse J, Rao G, Weinberg JS, Prabhu SS, McCutcheon IE, Lang FF, Ferguson SD, Sawaya R, Colen R, Yadav SS, Blando J, Vence L, Allison J, Sharma P, Heimberger AB. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol. 2020 04 15; 22(4):539-549. PMID: 31755915; PMCID: PMC7158647.
      Citations: 41     Fields:    Translation:HumansCells
    55. Khan S, Mittal S, McGee K, Alfaro-Munoz KD, Majd N, Balasubramaniyan V, de Groot JF. Role of Neutrophils and Myeloid-Derived Suppressor Cells in Glioma Progression and Treatment Resistance. Int J Mol Sci. 2020 Mar 13; 21(6). PMID: 32182988; PMCID: PMC7139844.
      Citations: 19     Fields:    Translation:HumansAnimalsCells
    56. Beccaria K, Sabbagh A, de Groot J, Heimberger AB, Canney M, Carpentier A. Blood-brain barrier opening with low intensity pulsed ultrasound for immune modulation and immune therapeutic delivery to CNS tumors. J Neurooncol. 2021 Jan; 151(1):65-73. PMID: 32112296.
      Citations: 15     Fields:    Translation:Humans
    57. Wei J, Chen P, Gupta P, Ott M, Zamler D, Kassab C, Bhat KP, Curran MA, de Groot JF, Heimberger AB. Immune biology of glioma-associated macrophages and microglia: functional and therapeutic implications. Neuro Oncol. 2020 02 20; 22(2):180-194. PMID: 31679017; PMCID: PMC7442334.
      Citations: 48     Fields:    Translation:HumansAnimalsCells
    58. Stewart CA, Gay CM, Xi Y, Sivajothi S, Sivakamasundari V, Fujimoto J, Bolisetty M, Hartsfield PM, Balasubramaniyan V, Chalishazar MD, Moran C, Kalhor N, Stewart J, Tran H, Swisher SG, Roth JA, Zhang J, de Groot J, Glisson B, Oliver TG, Heymach JV, Wistuba I, Robson P, Wang J, Byers LA. Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. Nat Cancer. 2020 04; 1:423-436. PMID: 33521652; PMCID: PMC7842382.
      Citations: 52     Translation:HumansCells
    59. Kamiya-Matsuoka C, Hamza MA, de Groot JF. Impact of adverse events of bevacizumab on survival outcomes of patients with recurrent glioblastoma. J Clin Neurosci. 2020 Apr; 74:36-40. PMID: 31982279.
      Citations:    Fields:    Translation:Humans
    60. Majd N, Dasgupta P, de Groot J. Immunotherapy for Neuro-Oncology. Adv Exp Med Biol. 2020; 1244:183-203. PMID: 32301015.
      Citations: 3     Fields:    Translation:Humans
    61. Goswami S, Walle T, Cornish AE, Basu S, Anandhan S, Fernandez I, Vence L, Blando J, Zhao H, Yadav SS, Ott M, Kong LY, Heimberger AB, de Groot J, Sepesi B, Overman M, Kopetz S, Allison JP, Pe'er D, Sharma P. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nat Med. 2020 01; 26(1):39-46. PMID: 31873309; PMCID: PMC7182038.
      Citations: 99     Fields:    Translation:HumansAnimalsCells
    62. Wu S, Gao F, Zheng S, Zhang C, Martinez-Ledesma E, Ezhilarasan R, Ding J, Li X, Feng N, Multani A, Sulman EP, Verhaak RG, de Groot JF, Heffernan TP, Yung WKA, Koul D. EGFR Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma. Clin Cancer Res. 2020 03 15; 26(6):1395-1407. PMID: 31852834.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    63. Majd N, Kamiya-Matsuoka C, de Groot J. The path forward for anti-programmed cell death-1 therapy in gliomas. Curr Opin Neurol. 2019 12; 32(6):864-871. PMID: 31567548.
      Citations: 1     Fields:    Translation:HumansAnimals
    64. Rogers CL, Won M, Vogelbaum MA, Perry A, Ashby LS, Modi JM, Alleman AM, Galvin J, Fogh SE, Youssef E, Deb N, Kwok Y, Robinson CG, Shu HK, Fisher BJ, McMillan WG, de Groot JF, Zhang P, Mehta MP, Panet-Raymond V. High-risk Meningioma: Initial Outcomes From NRG Oncology/RTOG 0539. Int J Radiat Oncol Biol Phys. 2020 03 15; 106(4):790-799. PMID: 31786276; PMCID: PMC7117785.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    65. Gammon ST, Pisaneschi F, Bandi ML, Smith MG, Sun Y, Rao Y, Muller F, Wong F, De Groot J, Ackroyd J, Mawlawi O, Davies MA, Gopal YNV, Di Francesco ME, Marszalek JR, Dewhirst M, Piwnica-Worms D. Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [18F]FAZA PET In Vivo. Cells. 2019 11 21; 8(12). PMID: 31766580; PMCID: PMC6952969.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    66. Barthel FP, Johnson KC, Varn FS, Moskalik AD, Tanner G, Kocakavuk E, Anderson KJ, Abiola O, Aldape K, Alfaro KD, Alpar D, Amin SB, Ashley DM, Bandopadhayay P, Barnholtz-Sloan JS, Beroukhim R, Bock C, Brastianos PK, Brat DJ, Brodbelt AR, Bruns AF, Bulsara KR, Chakrabarty A, Chakravarti A, Chuang JH, Claus EB, Cochran EJ, Connelly J, Costello JF, Finocchiaro G, Fletcher MN, French PJ, Gan HK, Gilbert MR, Grimmer MR, Iavarone A, Ismail A, Jenkinson MD, Khasraw M, Kim H, Kouwenhoven MCM, LaViolette PS, Li M, Lichter P, Ligon KL, Lowman AK, Malta TM, Mazor T, McDonald KL, Molinaro AM, Nam DH, Nayyar N, Ng HK, Ngan CY, Niclou SP, Niers JM, Noushmehr H, Noorbakhsh J, Ormond DR, Park CK, Poisson LM, Rabadan R, Radlwimmer B, Rao G, Sa JK, Schuster M, Shaw BL, Short SC, Smitt PAS, Sloan AE, Smits M, Suzuki H, Van Meir EG, Watts C, Weller M, Wesseling P, Westerman BA, Widhalm G, Woehrer A, Yung WKA, Zadeh G, Huse JT, De Groot JF, Stead LF, Verhaak RGW, GLASS Consortium, Gould PV, Reifenberger G, Tabatabai G. Longitudinal molecular trajectories of diffuse glioma in adults. Nature. 2019 12; 576(7785):112-120. PMID: 31748746; PMCID: PMC6897368.
      Citations: 112     Fields:    Translation:HumansCells
    67. Kesler SR, Harrison RA, Petersen ML, Rao V, Dyson H, Alfaro-Munoz K, Weathers SP, de Groot J. Pre-surgical connectome features predict IDH status in diffuse gliomas. Oncotarget. 2019 Nov 05; 10(60):6484-6493. PMID: 31741712; PMCID: PMC6849657.
      Citations: 3     Fields:    
    68. Majd N, Weathers SP, de Groot J. Are we AKT-ually getting closer to making targeted therapy successful in breast cancer brain metastases? Neuro Oncol. 2019 11 04; 21(11):1344-1345. PMID: 31515554; PMCID: PMC6827831.
      Citations:    Fields:    Translation:Humans
    69. Farooqi A, Li J, de Groot J, Yeboa DN. Current Role of Radiation Therapy in the Management of Malignant Central Nervous System Tumors. Hematol Oncol Clin North Am. 2020 02; 34(1):13-28. PMID: 31739940.
      Citations: 3     Fields:    Translation:Humans
    70. Youssef M, Ludmir EB, Mandel JJ, Patel AJ, Jalali A, Treiber J, Wu J, McAleer MF, de Groot JF. Treatment strategies for glioblastoma in older patients: age is just a number. J Neurooncol. 2019 Nov; 145(2):357-364. PMID: 31643011.
      Citations: 7     Fields:    Translation:Humans
    71. Lee EQ, Chukwueke UN, Hervey-Jumper SL, de Groot JF, Leone JP, Armstrong TS, Chang SM, Arons D, Oliver K, Verble K, Musella A, Willmarth N, Alexander BM, Bates A, Doherty L, Galanis E, Gaffey S, Halkin T, Friday BE, Fouladi M, Lin NU, Macdonald D, Mehta MP, Penas-Prado M, Vogelbaum MA, Sahebjam S, Sandak D, van den Bent M, Weller M, Reardon DA, Wen PY. Barriers to accrual and enrollment in brain tumor trials. Neuro Oncol. 2019 09 06; 21(9):1100-1117. PMID: 31175826; PMCID: PMC7594546.
      Citations: 27     Fields:    Translation:Humans
    72. Lim-Fat MJ, Bi WL, Lo J, Lee EQ, Ahluwalia MS, Batchelor TT, Chang SM, Chiocca EA, Chukwueke U, Cloughesy TF, Colman H, Deangelis LM, Galanis E, Gilbert MR, De Groot JF, Lassman AB, Liau LM, Mason W, McFaline-Figueroa JR, Mehta MP, Mellinghoff IK, Nabors LB, Nayak L, Reardon DA, Wen PY. Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. Neurosurgery. 2019 09 01; 85(3):E607-E608. PMID: 31215634; PMCID: PMC6904720.
      Citations: 2     Fields:    
    73. Majd N, de Groot J. Challenges and strategies for successful clinical development of immune checkpoint inhibitors in glioblastoma. Expert Opin Pharmacother. 2019 Sep; 20(13):1609-1624. PMID: 31264484.
      Citations: 3     Fields:    Translation:HumansCells
    74. Robins HI, Eickhoff J, Gilbert MR, Armstrong TS, Shi W, De Groot JF, Schultz CJ, Hunter GK, Roach M, Youssef EF, Howard SP, Lieberman FS, Herman JG, Zhang P, Mehta MP, Valeinis E, Souhami L. The association between BMI and BSA-temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525. Neurooncol Pract. 2019 Dec; 6(6):473-478. PMID: 31832217; PMCID: PMC6899045.
      Citations: 3     
    75. Harrison RA, Anderson MD, Cachia D, Kamiya-Matsuoka C, Weathers SS, O'Brien BJ, Penas-Prado M, Yung WKA, Wu J, Yuan Y, de Groot JF. Clinical trial participation of patients with glioblastoma at The University of Texas MD Anderson Cancer Center. Eur J Cancer. 2019 05; 112:83-93. PMID: 30951926.
      Citations: 7     Fields:    Translation:Humans
    76. Zheng S, Alfaro-Munoz K, Wei W, Wang X, Wang F, Eterovic AK, Shaw KRM, Meric-Bernstam F, Fuller GN, Chen K, Verhaak RG, Mills GB, Yung WKA, Weathers SP, de Groot JF. Prospective Clinical Sequencing of Adult Glioma. Mol Cancer Ther. 2019 05; 18(5):991-1000. PMID: 30926639; PMCID: PMC6497568.
      Citations: 5     Fields:    Translation:HumansCells
    77. Alexander BM, Trippa L, Gaffey S, Arrillaga-Romany IC, Lee EQ, Rinne ML, Ahluwalia MS, Colman H, Fell G, Galanis E, de Groot J, Drappatz J, Lassman AB, Meredith DM, Nabors LB, Santagata S, Schiff D, Welch MR, Ligon KL, Wen PY. Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma. JCO Precis Oncol. 2019; 3. PMID: 32914038; PMCID: PMC7448806.
      Citations: 19     Fields:    
    78. Ludmir EB, Mandel JJ, McAleer MF, de Groot JF. Disparities along the glioblastoma clinical trials landscape. Neuro Oncol. 2019 02 14; 21(2):285-286. PMID: 30476295; PMCID: PMC6374758.
      Citations: 3     Fields:    Translation:Humans
    79. Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, Kawaguchi ES, Du L, Li G, Yong WH, Gaffey SC, Cohen AL, Mellinghoff IK, Lee EQ, Reardon DA, O'Brien BJ, Butowski NA, Nghiemphu PL, Clarke JL, Arrillaga-Romany IC, Colman H, Kaley TJ, de Groot JF, Liau LM, Wen PY, Prins RM. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019 03; 25(3):477-486. PMID: 30742122; PMCID: PMC6408961.
      Citations: 381     Fields:    Translation:HumansCells
    80. Wen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S, McCluskey CS, Pelton K, Haidar S, Basu SS, Gaffey SC, Brown LE, Martinez-Ledesma JE, Wu S, Kim J, Wei W, Park MA, Huse JT, Kuhn JG, Rinne ML, Colman H, Agar NYR, Omuro AM, DeAngelis LM, Gilbert MR, de Groot JF, Cloughesy TF, Chi AS, Roberts TM, Zhao JJ, Lee EQ, Nayak L, Heath JR, Horky LL, Batchelor TT, Beroukhim R, Chang SM, Ligon AH, Dunn IF, Koul D, Young GS, Prados MD, Reardon DA, Yung WKA, Ligon KL. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. J Clin Oncol. 2019 03 20; 37(9):741-750. PMID: 30715997; PMCID: PMC6553812.
      Citations: 42     Fields:    Translation:HumansCellsCTClinical Trials
    81. Mandel JJ, Youssef M, Nam J, Patel AJ, Jalali A, Ludmir EB, Liu D, Wu J, Armstrong G, Huse J, Bondy M, de Groot JF. Effect of health disparities on overall survival of patients with glioblastoma. J Neurooncol. 2019 Apr; 142(2):365-374. PMID: 30671709.
      Citations: 5     Fields:    Translation:Humans
    82. D'Angelo F, Ceccarelli M, Garofano L, Zhang J, Caruso FP, Lewis G, Alfaro KD, Bauchet L, Cachia D, Cangiano M, de Groot J, DiMeco F, Farah W, Finocchiaro G, Kamiya-Matsuoka C, Loiseau H, McCutcheon I, Nam DH, Saletti V, Slopis J, Vandenbos F, Varlet P, Watts C, Tabar V, Reuss DE, Kim SK, Meyronet D, Bhat KP, Eoli M, Lasorella A, Iavarone A, Frattini V, Berzero G, Capelle L, Ducray F, Goutagny S, Lavarino C, Lorgis V, Marras CE, Ronchi S, Seizeur R, Su?ol M, Vidaud D, Mokhtari K, Salvador H, Sanson M. The molecular landscape of glioma in patients with Neurofibromatosis 1. Nat Med. 2019 01; 25(1):176-187. PMID: 30531922; PMCID: PMC6857804.
      Citations: 66     Fields:    Translation:HumansCells
    83. Schiff D, de Groot JF. Lower-grade gliomas: the wrong target for bevacizumab. Neuro Oncol. 2018 11 12; 20(12):1559-1560. PMID: 30418659; PMCID: PMC6231203.
      Citations:    Fields:    Translation:Humans
    84. Maraka S, Groves MD, Mammoser AG, Melguizo-Gavilanes I, Conrad CA, Tremont-Lukats IW, Loghin ME, O'Brien BJ, Puduvalli VK, Sulman EP, Hess KR, Aldape KD, Gilbert MR, de Groot JF, Alfred Yung WK, Penas-Prado M. Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma. Cancer. 2019 02 01; 125(3):424-433. PMID: 30359477; PMCID: PMC7180384.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    85. Ding X, Wang Z, Chen D, Wang Y, Zhao Z, Sun C, Chen D, Tang C, Xiong J, Chen L, Yao Z, Liu Y, Wang X, Cahill DP, de Groot JF, Jiang T, Yao Y, Zhou L. The prognostic value of maximal surgical resection is attenuated in oligodendroglioma subgroups of adult diffuse glioma: a multicenter retrospective study. J Neurooncol. 2018 Dec; 140(3):591-603. PMID: 30206763.
      Citations: 8     Fields:    Translation:Humans
    86. Ellingson BM, Aftab DT, Schwab GM, Hessel C, Harris RJ, Woodworth DC, Leu K, Chakhoyan A, Raymond C, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Holland J, Ping J, Weitzman R, Wen PY, Cloughesy TF. Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma. Neuro Oncol. 2018 09 03; 20(10):1411-1418. PMID: 29660005; PMCID: PMC6120362.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    87. Ellingson BM, Abrey LE, Nelson SJ, Kaufmann TJ, Garcia J, Chinot O, Saran F, Nishikawa R, Mason WP, Wick W, Butowski N, Ligon KL, Gerstner ER, Colman H, de Groot J, Chang S, Mellinghoff I, Young RJ, Alexander BM, Colen R, Taylor JW, Arrillaga-Romany I, Mehta A, Huang RY, Pope WB, Reardon D, Batchelor T, Prados M, Galanis E, Wen PY, Cloughesy TF, Henriksson R. Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Neuro Oncol. 2018 08 02; 20(9):1240-1250. PMID: 29660006; PMCID: PMC6071654.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    88. Harrison RA, de Groot JF. Treatment of Glioblastoma in the Elderly. Drugs Aging. 2018 Aug; 35(8):707-718. PMID: 30039343.
      Citations: 5     Fields:    Translation:Humans
    89. Zinn PO, Singh SK, Kotrotsou A, Hassan I, Thomas G, Luedi MM, Elakkad A, Elshafeey N, Idris T, Mosley J, Gumin J, Fuller GN, de Groot JF, Baladandayuthapani V, Sulman EP, Kumar AJ, Sawaya R, Lang FF, Piwnica-Worms D, Colen RR. A Coclinical Radiogenomic Validation Study: Conserved Magnetic Resonance Radiomic Appearance of Periostin-Expressing Glioblastoma in Patients and Xenograft Models. Clin Cancer Res. 2018 12 15; 24(24):6288-6299. PMID: 30054278; PMCID: PMC6538261.
      Citations: 37     Fields:    Translation:HumansAnimals
    90. Mandel JJ, Youssef M, Ludmir E, Yust-Katz S, Patel AJ, De Groot JF. Highlighting the need for reliable clinical trials in glioblastoma. Expert Rev Anticancer Ther. 2018 10; 18(10):1031-1040. PMID: 29973092.
      Citations: 9     Fields:    Translation:Humans
    91. Molina JR, Sun Y, Protopopova M, Gera S, Bandi M, Bristow C, McAfoos T, Morlacchi P, Ackroyd J, Agip AA, Al-Atrash G, Asara J, Bardenhagen J, Carrillo CC, Carroll C, Chang E, Ciurea S, Cross JB, Czako B, Deem A, Daver N, de Groot JF, Dong JW, Feng N, Gao G, Gay J, Do MG, Greer J, Giuliani V, Han J, Han L, Henry VK, Hirst J, Huang S, Jiang Y, Kang Z, Khor T, Konoplev S, Lin YH, Liu G, Lodi A, Lofton T, Ma H, Mahendra M, Matre P, Mullinax R, Peoples M, Petrocchi A, Rodriguez-Canale J, Serreli R, Shi T, Smith M, Tabe Y, Theroff J, Tiziani S, Xu Q, Zhang Q, Muller F, DePinho RA, Toniatti C, Draetta GF, Heffernan TP, Konopleva M, Jones P, Di Francesco ME, Marszalek JR. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat Med. 2018 07; 24(7):1036-1046. PMID: 29892070.
      Citations: 261     Fields:    Translation:HumansAnimalsCells
    92. Ferguson SD, Zhou S, Huse JT, de Groot JF, Xiu J, Subramaniam DS, Mehta S, Gatalica Z, Swensen J, Sanai N, Spetzler D, Heimberger AB. Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas. J Neuropathol Exp Neurol. 2018 06 01; 77(6):437-442. PMID: 29718398; PMCID: PMC5961205.
      Citations: 22     Fields:    Translation:HumansCells
    93. Kotrotsou A, Elakkad A, Sun J, Thomas GA, Yang D, Abrol S, Wei W, Weinberg JS, Bakhtiari AS, Kircher MF, Luedi MM, de Groot JF, Sawaya R, Kumar AJ, Zinn PO, Colen RR. Multi-center study finds postoperative residual non-enhancing component of glioblastoma as a new determinant of patient outcome. J Neurooncol. 2018 Aug; 139(1):125-133. PMID: 29619649.
      Citations: 9     Fields:    Translation:Humans
    94. Wen PY, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Holland J, Ping J, Weitzman R, Cloughesy TF. Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy. Neuro Oncol. 2018 01 22; 20(2):249-258. PMID: 29016998; PMCID: PMC5777496.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    95. Cloughesy TF, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Ping J, Holland J, Weitzman R, Wen PY. Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy. Neuro Oncol. 2018 01 22; 20(2):259-267. PMID: 29036345; PMCID: PMC5777491.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    96. Mandel JJ, Yust-Katz S, Patel AJ, Cachia D, Liu D, Park M, Yuan Y, Kent TA, de Groot JF. Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma. Neuro Oncol. 2018 01 10; 20(1):113-122. PMID: 29016865; PMCID: PMC5761583.
      Citations: 20     Fields:    Translation:Humans
    97. Dong J, Park SY, Nguyen N, Ezhilarasan R, Martinez-Ledesma E, Wu S, Henry V, Piao Y, Tiao N, Brunell D, Stephan C, Verhaak R, Sulman E, Balasubramaniyan V, de Groot JF. The polo-like kinase 1 inhibitor volasertib synergistically increases radiation efficacy in glioma stem cells. Oncotarget. 2018 Feb 13; 9(12):10497-10509. PMID: 29535822; PMCID: PMC5828226.
      Citations: 8     Fields:    
    98. Ferguson SD, Zhou S, Xiu J, Hashimoto Y, Sanai N, Kim L, Kesari S, de Groot J, Spetzler D, Heimberger AB. Ependymomas overexpress chemoresistance and DNA repair-related proteins. Oncotarget. 2018 Jan 30; 9(8):7822-7831. PMID: 29487694; PMCID: PMC5814261.
      Citations: 4     Fields:    
    99. Schomann T, Mezzanotte L, De Groot JCMJ, Rivolta MN, Hendriks SH, Frijns JHM, Huisman MA. Neuronal differentiation of hair-follicle-bulge-derived stem cells co-cultured with mouse cochlear modiolus explants. PLoS One. 2017; 12(10):e0187183. PMID: 29084289; PMCID: PMC5662184.
      Citations: 3     Fields:    Translation:AnimalsCells
    100. Byron SA, Tran NL, Halperin RF, Phillips JJ, Kuhn JG, de Groot JF, Colman H, Ligon KL, Wen PY, Cloughesy TF, Mellinghoff IK, Butowski NA, Taylor JW, Clarke JL, Chang SM, Berger MS, Molinaro AM, Maggiora GM, Peng S, Nasser S, Liang WS, Trent JM, Berens ME, Carpten JD, Craig DW, Prados MD. Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma. Clin Cancer Res. 2018 01 15; 24(2):295-305. PMID: 29074604; PMCID: PMC7516926.
      Citations: 25     Fields:    Translation:Humans
    101. Lee JH, Liu R, Li J, Zhang C, Wang Y, Cai Q, Qian X, Xia Y, Zheng Y, Piao Y, Chen Q, de Groot JF, Jiang T, Lu Z. Stabilization of phosphofructokinase 1 platelet isoform by AKT promotes tumorigenesis. Nat Commun. 2017 10 16; 8(1):949. PMID: 29038421; PMCID: PMC5643558.
      Citations: 63     Fields:    Translation:HumansCells
    102. Boonyawan K, Hess KR, Yang J, Long L, Wang Q, Ezhilarasan R, Auia A, Alfaro-Munoz KD, de Groot JF, Bhat KP, Sulman EP. A relative increase in circulating platelets following chemoradiation predicts for poor survival of patients with glioblastoma. Oncotarget. 2017 Oct 27; 8(52):90488-90495. PMID: 29163847; PMCID: PMC5685768.
      Citations: 7     Fields:    
    103. Rogers L, Zhang P, Vogelbaum MA, Perry A, Ashby LS, Modi JM, Alleman AM, Galvin J, Brachman D, Jenrette JM, De Groot J, Bovi JA, Werner-Wasik M, Knisely JPS, Mehta MP. Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. J Neurosurg. 2018 07; 129(1):35-47. PMID: 28984517; PMCID: PMC5889346.
      Citations: 61     Fields:    Translation:HumansCTClinical Trials
    104. Nam JY, de Groot JF. Treatment of Glioblastoma. J Oncol Pract. 2017 10; 13(10):629-638. PMID: 29020535.
      Citations: 47     Fields:    Translation:HumansCells
    105. Penas-Prado M, de Groot J. CATNON interim results: another triumph of upfront chemotherapy in glioma. Neuro Oncol. 2017 10 01; 19(10):1287-1288. PMID: 28922864; PMCID: PMC5596163.
      Citations: 1     Fields:    Translation:Humans
    106. Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018 Jan; 15(1):47-62. PMID: 28925994; PMCID: PMC6733403.
      Citations: 631     Fields:    Translation:Humans
    107. Daher A, de Groot J. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model. Exp Neurol. 2018 01; 299(Pt B):281-288. PMID: 28923369.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    108. Hodges TR, Ott M, Xiu J, Gatalica Z, Swensen J, Zhou S, Huse JT, de Groot J, Li S, Overwijk WW, Spetzler D, Heimberger AB. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro Oncol. 2017 Aug 01; 19(8):1047-1057. PMID: 28371827; PMCID: PMC5570198.
      Citations: 165     Fields:    Translation:HumansCells
    109. Piao Y, Henry V, Tiao N, Park SY, Martinez-Ledesma J, Dong JW, Balasubramaniyan V, de Groot JF. Targeting intercellular adhesion molecule-1 prolongs survival in mice bearing bevacizumab-resistant glioblastoma. Oncotarget. 2017 Nov 14; 8(57):96970-96983. PMID: 29228586; PMCID: PMC5722538.
      Citations: 15     Fields:    
    110. Ellingson BM, Gerstner ER, Smits M, Huang RY, Colen R, Abrey LE, Aftab DT, Schwab GM, Hessel C, Harris RJ, Chakhoyan A, Gahrmann R, Pope WB, Leu K, Raymond C, Woodworth DC, de Groot J, Wen PY, Batchelor TT, van den Bent MJ, Cloughesy TF. Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials. Clin Cancer Res. 2017 Oct 01; 23(19):5745-5756. PMID: 28655794; PMCID: PMC5626594.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    111. Harrison RA, de Groot JF. Cell Signaling Pathways in Brain Tumors. Top Magn Reson Imaging. 2017 Feb; 26(1):15-26. PMID: 28079711.
      Citations: 1     Fields:    Translation:HumansCells
    112. Burstein HJ, Krilov L, Aragon-Ching JB, Baxter NN, Chiorean EG, Chow WA, De Groot JF, Devine SM, DuBois SG, El-Deiry WS, Epstein AS, Heymach J, Jones JA, Mayer DK, Miksad RA, Pennell NA, Sabel MS, Schilsky RL, Schuchter LM, Tung N, Winkfield KM, Wirth LJ, Dizon DS. Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2017 04 20; 35(12):1341-1367. PMID: 28148207.
      Citations: 31     Fields:    Translation:Humans
    113. Nayak L, de Groot J, Wefel JS, Cloughesy TF, Lieberman F, Chang SM, Omuro A, Drappatz J, Batchelor TT, DeAngelis LM, Gilbert MR, Aldape KD, Yung AW, Fisher J, Ye X, Chen A, Grossman S, Prados M, Wen PY. Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. J Neurooncol. 2017 03; 132(1):181-188. PMID: 28116649; PMCID: PMC5588922.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    114. Schomann T, Mezzanotte L, Lourens IM, de Groot JC, Frijns JH, Huisman MA. Lentiviral transduction and subsequent loading with nanoparticles do not affect cell viability and proliferation in hair-follicle-bulge-derived stem cells in vitro. Contrast Media Mol Imaging. 2016 11; 11(6):550-560. PMID: 27976505.
      Citations: 5     Fields:    Translation:AnimalsCells
    115. Cohen JV, Tawbi H, Margolin KA, Amravadi R, Bosenberg M, Brastianos PK, Chiang VL, de Groot J, Glitza IC, Herlyn M, Holmen SL, Jilaveanu LB, Lassman A, Moschos S, Postow MA, Thomas R, Tsiouris JA, Wen P, White RM, Turnham T, Davies MA, Kluger HM. Melanoma central nervous system metastases: current approaches, challenges, and opportunities. Pigment Cell Melanoma Res. 2016 11; 29(6):627-642. PMID: 27615400; PMCID: PMC5398760.
      Citations: 41     Fields:    Translation:Humans
    116. O'Neill AF, Qin L, Wen PY, de Groot JF, Van den Abbeele AD, Yap JT. Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma. J Neurooncol. 2016 12; 130(3):495-503. PMID: 27576699.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    117. Weathers SP, Han X, Liu DD, Conrad CA, Gilbert MR, Loghin ME, O'Brien BJ, Penas-Prado M, Puduvalli VK, Tremont-Lukats I, Colen RR, Yung WKA, de Groot JF. A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma. J Neurooncol. 2016 09; 129(3):487-494. PMID: 27406589; PMCID: PMC5021605.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    118. Garber ST, Hashimoto Y, Weathers SP, Xiu J, Gatalica Z, Verhaak RG, Zhou S, Fuller GN, Khasraw M, de Groot J, Reddy SK, Spetzler D, Heimberger AB. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro Oncol. 2016 10; 18(10):1357-66. PMID: 27370400; PMCID: PMC5035527.
      Citations: 76     Fields:    Translation:HumansCells
    119. Park SY, Piao Y, Jeong KJ, Dong J, de Groot JF. Periostin (POSTN) Regulates Tumor Resistance to Antiangiogenic Therapy in Glioma Models. Mol Cancer Ther. 2016 09; 15(9):2187-97. PMID: 27307601; PMCID: PMC5104278.
      Citations: 36     Fields:    Translation:HumansAnimalsCells
    120. Mandel JJ, Cachia D, Liu D, Wilson C, Aldape K, Fuller G, de Groot JF. Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma. J Neurooncol. 2016 08; 129(1):147-54. PMID: 27270908; PMCID: PMC5021066.
      Citations: 18     Fields:    Translation:Humans
    121. Park SY, Piao Y, Thomas C, Fuller GN, de Groot JF. Cdc2-like kinase 2 is a key regulator of the cell cycle via FOXO3a/p27 in glioblastoma. Oncotarget. 2016 May 03; 7(18):26793-805. PMID: 27050366; PMCID: PMC5042015.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    122. Piao Y, Park SY, Henry V, Smith BD, Tiao N, Flynn DL, de Groot JF. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models. Neuro Oncol. 2016 09; 18(9):1230-41. PMID: 26965451; PMCID: PMC4998992.
      Citations: 33     Fields:    Translation:HumansAnimalsCells
    123. Hodges TR, Ferguson SD, Caruso HG, Kohanbash G, Zhou S, Cloughesy TF, Berger MS, Poste GH, Khasraw M, Ba S, Jiang T, Mikkelson T, Yung WK, de Groot JF, Fine H, Cantley LC, Mellinghoff IK, Mitchell DA, Okada H, Heimberger AB. Prioritization schema for immunotherapy clinical trials in glioblastoma. Oncoimmunology. 2016 Jun; 5(6):e1145332. PMID: 27471611; PMCID: PMC4938323.
      Citations: 10     Fields:    
    124. Gatson NT, Weathers SP, de Groot JF. ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma. CNS Oncol. 2016; 5(1):11-26. PMID: 26670466; PMCID: PMC6078156.
      Citations: 8     Fields:    
    125. Robins HI, Zhang P, Gilbert MR, Chakravarti A, de Groot JF, Grimm SA, Wang F, Lieberman FS, Krauze A, Trotti AM, Mohile N, Kee AY, Colman H, Cavaliere R, Kesari S, Chmura SJ, Mehta M. A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study. J Neurooncol. 2016 Jan; 126(2):309-16. PMID: 26508094; PMCID: PMC4720526.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    126. Liang J, Piao Y, Henry V, Tiao N, de Groot JF. Interferon-regulatory factor-1 (IRF1) regulates bevacizumab induced autophagy. Oncotarget. 2015 Oct 13; 6(31):31479-92. PMID: 26362401; PMCID: PMC4741619.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    127. Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, Perry A, Huse J, Phillips J, West BL, Nolop KB, Hsu HH, Ligon KL, Molinaro AM, Prados M. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol. 2016 Apr; 18(4):557-64. PMID: 26449250; PMCID: PMC4799682.
      Citations: 215     Fields:    Translation:HumansCTClinical Trials
    128. Webre C, Shonka N, Smith L, Liu D, De Groot J. PC or PCV, That Is the Question: Primary Anaplastic Oligodendroglial Tumors Treated with Procarbazine and CCNU With and Without Vincristine. Anticancer Res. 2015 Oct; 35(10):5467-72. PMID: 26408710.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    129. Weathers SP, de Groot J. VEGF Manipulation in Glioblastoma. Oncology (Williston Park). 2015 Oct; 29(10):720-7. PMID: 26470893.
      Citations: 36     Fields:    Translation:Humans
    130. Cachia D, Kamiya-Matsuoka C, Mandel JJ, Olar A, Cykowski MD, Armstrong TS, Fuller GN, Gilbert MR, De Groot JF. Primary and secondary gliosarcomas: clinical, molecular and survival characteristics. J Neurooncol. 2015 Nov; 125(2):401-10. PMID: 26354773; PMCID: PMC8323586.
      Citations: 22     Fields:    Translation:Humans
    131. Meric-Bernstam F, Brusco L, Shaw K, Horombe C, Kopetz S, Davies MA, Routbort M, Piha-Paul SA, Janku F, Ueno N, Hong D, De Groot J, Ravi V, Li Y, Luthra R, Patel K, Broaddus R, Mendelsohn J, Mills GB. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. J Clin Oncol. 2015 Sep 01; 33(25):2753-62. PMID: 26014291; PMCID: PMC4550690.
      Citations: 203     Fields:    Translation:Humans
    132. Prados MD, Byron SA, Tran NL, Phillips JJ, Molinaro AM, Ligon KL, Wen PY, Kuhn JG, Mellinghoff IK, de Groot JF, Colman H, Cloughesy TF, Chang SM, Ryken TC, Tembe WD, Kiefer JA, Berens ME, Craig DW, Carpten JD, Trent JM. Toward precision medicine in glioblastoma: the promise and the challenges. Neuro Oncol. 2015 Aug; 17(8):1051-63. PMID: 25934816; PMCID: PMC4490873.
      Citations: 93     Fields:    Translation:Humans
    133. Theeler BJ, Ellezam B, Melguizo-Gavilanes I, de Groot JF, Mahajan A, Aldape KD, Bruner JM, Puduvalli VK. Adult brainstem gliomas: Correlation of clinical and molecular features. J Neurol Sci. 2015; 353(1-2):92-7. PMID: 25934342; PMCID: PMC4782610.
      Citations: 15     Fields:    Translation:Humans
    134. de Groot JF. High-grade gliomas. Continuum (Minneap Minn). 2015 Apr; 21(2 Neuro-oncology):332-44. PMID: 25837899.
      Citations: 17     Fields:    Translation:Humans
    135. Martinez-Ledesma E, de Groot JF, Verhaak RG. Seek and destroy: relating cancer drivers to therapies. Cancer Cell. 2015 Mar 09; 27(3):319-21. PMID: 25759016.
      Citations: 4     Fields:    Translation:Humans
    136. Chen K, Meric-Bernstam F, Zhao H, Zhang Q, Ezzeddine N, Tang LY, Qi Y, Mao Y, Chen T, Chong Z, Zhou W, Zheng X, Johnson A, Aldape KD, Routbort MJ, Luthra R, Kopetz S, Davies MA, de Groot J, Moulder S, Vinod R, Farhangfar CJ, Shaw KM, Mendelsohn J, Mills GB, Eterovic AK. Clinical actionability enhanced through deep targeted sequencing of solid tumors. Clin Chem. 2015 Mar; 61(3):544-53. PMID: 25626406; PMCID: PMC4511273.
      Citations: 61     Fields:    Translation:Humans
    137. Mella DB, Kamiya-Matsuoka C, Liao B, Tummala S, de Groot J. Recurrent encephaloclastic cyst induced by intraventricular topotecan. J Neurol Sci. 2015 Feb 15; 349(1-2):52-3. PMID: 25598491.
      Citations: 1     Fields:    Translation:Humans
    138. Batchelor TT, Reardon DA, de Groot JF, Wick W, Weller M. Antiangiogenic therapy for glioblastoma: current status and future prospects. Clin Cancer Res. 2014 Nov 15; 20(22):5612-9. PMID: 25398844; PMCID: PMC4234180.
      Citations: 61     Fields:    Translation:Humans
    139. Schiff D, Kesari S, de Groot J, Mikkelsen T, Drappatz J, Coyle T, Fichtel L, Silver B, Walters I, Reardon D. Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma. Invest New Drugs. 2015 Feb; 33(1):247-53. PMID: 25388940.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    140. Penas-Prado M, Hess KR, Fisch MJ, Lagrone LW, Groves MD, Levin VA, De Groot JF, Puduvalli VK, Colman H, Volas-Redd G, Giglio P, Conrad CA, Salacz ME, Floyd JD, Loghin ME, Hsu SH, Gonzalez J, Chang EL, Woo SY, Mahajan A, Aldape KD, Yung WK, Gilbert MR, MD Anderson Community Clinical Oncology Program, Brain Tumor Trials Collaborative. Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. Neuro Oncol. 2015 Feb; 17(2):266-73. PMID: 25239666; PMCID: PMC4288521.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    141. Mandel JJ, Yust-Katz S, Cachia D, Wu J, Liu D, de Groot JF, Yung AW, Gilbert MR. Leptomeningeal dissemination in glioblastoma; an inspection of risk factors, treatment, and outcomes at a single institution. J Neurooncol. 2014 Dec; 120(3):597-605. PMID: 25168214.
      Citations: 19     Fields:    Translation:Humans
    142. Alexander BM, Galanis E, Yung WK, Ballman KV, Boyett JM, Cloughesy TF, Degroot JF, Huse JT, Mann B, Mason W, Mellinghoff IK, Mikkelsen T, Mischel PS, O'Neill BP, Prados MD, Sarkaria JN, Tawab-Amiri A, Trippa L, Ye X, Ligon KL, Berry DA, Wen PY. Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group. Neuro Oncol. 2015 Feb; 17(2):180-8. PMID: 25165194; PMCID: PMC4288520.
      Citations: 11     Fields:    Translation:Humans
    143. Theeler BJ, Ellezam B, Yust-Katz S, Slopis JM, Loghin ME, de Groot JF. Prolonged survival in adult neurofibromatosis type I patients with recurrent high-grade gliomas treated with bevacizumab. J Neurol. 2014 Aug; 261(8):1559-64. PMID: 24859329.
      Citations: 8     Fields:    Translation:Humans
    144. Hamza MA, Mandel JJ, Conrad CA, Gilbert MR, Yung WK, Puduvalli VK, DeGroot JF. Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma. J Neurooncol. 2014 Aug; 119(1):135-40. PMID: 24803001; PMCID: PMC4297475.
      Citations: 18     Fields:    Translation:Humans
    145. Weathers SP, de Groot J. Resistance to antiangiogenic therapy. Curr Neurol Neurosci Rep. 2014 May; 14(5):443. PMID: 24652451.
      Citations: 8     Fields:    Translation:HumansAnimals
    146. de Groot JF, Mandel JJ. Update on anti-angiogenic treatment for malignant gliomas. Curr Oncol Rep. 2014 Apr; 16(4):380. PMID: 24510742.
      Citations: 9     Fields:    Translation:Humans
    147. Guan X, Vengoechea J, Zheng S, Sloan AE, Chen Y, Brat DJ, O'Neill BP, de Groot J, Yust-Katz S, Yung WK, Cohen ML, Aldape KD, Rosenfeld S, Verhaak RG, Barnholtz-Sloan JS. Molecular subtypes of glioblastoma are relevant to lower grade glioma. PLoS One. 2014; 9(3):e91216. PMID: 24614622; PMCID: PMC3948818.
      Citations: 45     Fields:    Translation:HumansCells
    148. Yust-Katz S, de Groot JF, Liu D, Wu J, Yuan Y, Anderson MD, Conrad CA, Milbourne A, Gilbert MR, Armstrong TS. Pregnancy and glial brain tumors. Neuro Oncol. 2014 Sep; 16(9):1289-94. PMID: 24615863; PMCID: PMC4136891.
      Citations: 19     Fields:    Translation:Humans
    149. Yust-Katz S, Anderson MD, Liu D, Wu J, Yuan Y, Olar A, Fuller GN, Brown PD, de-Groot JF. Clinical and prognostic features of adult patients with gangliogliomas. Neuro Oncol. 2014 Mar; 16(3):409-13. PMID: 24305706; PMCID: PMC3922509.
      Citations: 13     Fields:    Translation:Humans
    150. Barney CL, Brown AP, Grosshans DR, McAleer MF, de Groot JF, Puduvalli V, Tucker SL, Crawford CN, Gilbert MR, Brown PD, Mahajan A. Technique, outcomes, and acute toxicities in adults treated with proton beam craniospinal irradiation. Neuro Oncol. 2014 Jan; 16(2):303-9. PMID: 24311638; PMCID: PMC3895378.
      Citations: 13     Fields:    Translation:Humans
    151. Kamiya-Matsuoka C, Garciarena P, Amin HM, Tremont-Lukats IW, de Groot JF. B lymphoblastic leukemia/lymphoma presenting as seventh cranial nerve palsy. Neurol Clin Pract. 2013 Dec; 3(6):532-534. PMID: 30107017; PMCID: PMC6082360.
    152. Liang J, Piao Y, Holmes L, Fuller GN, Henry V, Tiao N, de Groot JF. Neutrophils promote the malignant glioma phenotype through S100A4. Clin Cancer Res. 2014 Jan 01; 20(1):187-98. PMID: 24240114; PMCID: PMC4422653.
      Citations: 112     Fields:    Translation:HumansAnimalsCells
    153. Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, Mason W, Mikkelsen T, Phuphanich S, Ashby LS, Degroot J, Gattamaneni R, Cher L, Rosenthal M, Payer F, Jain RK, Sorensen AG, Xu J, Liu Q, van den Bent M, Batchelor TT, J?rgensmeier JM. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol. 2013 Sep 10; 31(26):3212-8. PMID: 23940216; PMCID: PMC4021043.
      Citations: 236     Fields:    Translation:HumansCTClinical Trials
    154. Piao Y, Liang J, Holmes L, Henry V, Sulman E, de Groot JF. Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition. Clin Cancer Res. 2013 Aug 15; 19(16):4392-403. PMID: 23804423.
      Citations: 92     Fields:    Translation:HumansAnimalsCells
    155. Chen SE, Choi SS, Rogers JE, Lei X, De Groot JF. Isotretinoin maintenance therapy for glioblastoma: a retrospective review. J Oncol Pharm Pract. 2014 Apr; 20(2):112-9. PMID: 23676507.
      Citations: 1     Fields:    Translation:Humans
    156. Brown AP, Barney CL, Grosshans DR, McAleer MF, de Groot JF, Puduvalli VK, Tucker SL, Crawford CN, Khan M, Khatua S, Gilbert MR, Brown PD, Mahajan A. Proton beam craniospinal irradiation reduces acute toxicity for adults with medulloblastoma. Int J Radiat Oncol Biol Phys. 2013 Jun 01; 86(2):277-84. PMID: 23433794; PMCID: PMC3954470.
      Citations: 52     Fields:    Translation:Humans
    157. Shonka N, Piao Y, Gilbert M, Yung A, Chang S, DeAngelis LM, Lassman AB, Liu J, Cloughesy T, Robins HI, Lloyd R, Chen A, Prados M, Wen PY, Heymach J, de Groot J. Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept. Target Oncol. 2013 Jun; 8(2):117-25. PMID: 23345034; PMCID: PMC4802008.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    158. de Groot J, Reardon DA, Batchelor TT. Antiangiogenic therapy for glioblastoma: the challenge of translating response rate into efficacy. Am Soc Clin Oncol Educ Book. 2013. PMID: 23714460.
      Citations: 7     Fields:    Translation:HumansCells
    159. de Groot JF. Prediction of response to chemotherapy in anaplastic glioma: how many markers does it take? J Clin Oncol. 2013 Jan 20; 31(3):297-8. PMID: 23269985.
      Citations: 2     Fields:    Translation:Humans
    160. Wang M, Dignam JJ, Zhang QE, DeGroot JF, Mehta MP, Hunsberger S. Integrated phase II/III clinical trials in oncology: a case study. Clin Trials. 2012 Dec; 9(6):741-7. PMID: 23180870; PMCID: PMC7099526.
      Citations: 2     Fields:    Translation:Humans
    161. Shonka N, Brandes A, De Groot JF. Adult medulloblastoma, from spongioblastoma cerebelli to the present day: a review of treatment and the integration of molecular markers. Oncology (Williston Park). 2012 Nov; 26(11):1083-91. PMID: 23330353.
      Citations: 1     Fields:    Translation:Humans
    162. Theeler BJ, Yung WK, Fuller GN, De Groot JF. Moving toward molecular classification of diffuse gliomas in adults. Neurology. 2012 Oct 30; 79(18):1917-26. PMID: 23109653; PMCID: PMC3525311.
      Citations: 33     Fields:    Translation:Humans
    163. Piao Y, Liang J, Holmes L, Zurita AJ, Henry V, Heymach JV, de Groot JF. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. Neuro Oncol. 2012 Nov; 14(11):1379-92. PMID: 22965162; PMCID: PMC3480262.
      Citations: 118     Fields:    Translation:HumansAnimalsCells
    164. de Groot J, Liang J, Kong LY, Wei J, Piao Y, Fuller G, Qiao W, Heimberger AB. Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma. Oncotarget. 2012 Sep; 3(9):1036-48. PMID: 23013619; PMCID: PMC3660053.
      Citations: 44     Fields:    Translation:HumansAnimalsCells
    165. Grossmann KF, Colman H, Akerley WA, Glantz M, Matsuoko Y, Beelen AP, Yu M, De Groot JF, Aiken RD, Olson JJ, Olsen JJ, Evans BA, Jensen RL. Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme. J Neurooncol. 2012 Nov; 110(2):257-64. PMID: 22932984.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    166. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, Al-Younes HM, Al-Zeer MA, Albert ML, Albin RL, Alegre-Abarrategui J, Aleo MF, Alirezaei M, Almasan A, Almonte-Becerril M, Amano A, Amaravadi R, Amarnath S, Amer AO, Andrieu-Abadie N, Anantharam V, Ann DK, Anoopkumar-Dukie S, Aoki H, Apostolova N, Arancia G, Aris JP, Asanuma K, Asare NY, Ashida H, Askanas V, Askew DS, Auberger P, Baba M, Backues SK, Baehrecke EH, Bahr BA, Bai XY, Bailly Y, Baiocchi R, Baldini G, Balduini W, Ballabio A, Bamber BA, Bampton ET, Bartholomew CR, Bassham DC, Bast RC, Batoko H, Bay BH, Beau I, Begley TJ, Behl C, Behrends C, Bekri S, Bellaire B, Bendall LJ, Benetti L, Berliocchi L, Bernardi H, Bernassola F, Bhatia-Kissova I, Bi X, Biard-Piechaczyk M, Blum JS, Boise LH, Bonaldo P, Boone DL, Bornhauser BC, Bortoluci KR, Bossis I, Bourquin JP, Boya P, Bozhkov PV, Brady NR, Brancolini C, Brech A, Brenman JE, Brennand A, Bresnick EH, Brest P, Bridges D, Bristol ML, Brookes PS, Brown EJ, Brumell JH, Brunetti-Pierri N, Brunk UT, Bulman DE, Bultman SJ, Bultynck G, Burbulla LF, Bursch W, Butchar JP, Buzgariu W, Bydlowski SP, Cadwell K, Cai D, Cai J, Cai Q, Calabretta B, Calvo-Garrido J, Camougrand N, Campanella M, Campos-Salinas J, Candi E, Cao L, Caplan AB, Carding SR, Cardoso SM, Carew JS, Carlin CR, Carmignac V, Carneiro LA, Carra S, Caruso RA, Casari G, Casas C, Castino R, Cebollero E, Cecconi F, Celli J, Chaachouay H, Chae HJ, Chai CY, Chan DC, Chan EY, Chang RC, Che CM, Chen CC, Chen GC, Chen GQ, Chen M, Chen Q, Chen SS, Chen W, Chen X, Chen X, Chen X, Chen YG, Chen Y, Chen Y, Chen YJ, Chen Z, Cheng A, Cheng CH, Cheng Y, Cheong H, Cheong JH, Cherry S, Chess-Williams R, Cheung ZH, Chevet E, Chiang HL, Chiarelli R, Chiba T, Chin LS, Chiou SH, Chisari FV, Cho CH, Cho DH, Choi AM, Choi D, Choi KS, Choi ME, Chouaib S, Choubey D, Choubey V, Chu CT, Chuang TH, Chueh SH, Chun T, Chwae YJ, Chye ML, Ciarcia R, Ciriolo MR, Clague MJ, Clark RS, Clarke PG, Clarke R, Codogno P, Coller HA, Comincini S, Condello M, Condorelli F, Cookson MR, Coombs GH, Coppens I, Corbalan R, Cossart P, Costelli P, Costes S, Coto-Montes A, Couve E, Coxon FP, Cregg JM, Cuervo AM, Cullen JJ, Czaja MJ, D'Amelio M, Darfeuille-Michaud A, Davids LM, Davies FE, De Felici M, de Groot JF, de Haan CA, De Martino L, De Milito A, De Tata V, Debnath J, Degterev A, Dehay B, Delbridge LM, Demarchi F, Deng YZ, Dent P, Denton D, Deretic V, Desai SD, Devenish RJ, Di Gioacchino M, Di Paolo G, Di Pietro C, Diaz-Meco MT, Diaz-Nido J, Dikic I, Dinesh-Kumar SP, Ding WX, Distelhorst CW, Diwan A, Djavaheri-Mergny M, Dokudovskaya S, Dong Z, Dorsey FC, Dosenko V, Dowling JJ, Doxsey S, Drew ME, Duan Q, Duchosal MA, Duff K, Dugail I, Durbeej M, Duszenko M, Edelstein CL, Edinger AL, Egea G, Eichinger L, Eissa NT, Ekmekcioglu S, El-Deiry WS, Elazar Z, Elgendy M, Ellerby LM, Eng KE, Engelbrecht AM, Engelender S, Erenpreisa J, Escalante R, Esclatine A, Eskelinen EL, Espert L, Espina V, Fan H, Fan J, Fan QW, Fan Z, Fang S, Fang Y, Fanto M, Fanzani A, Farkas T, Faure M, Fechheimer M, Feng CG, Feng J, Feng Q, Feng Y, Feuer R, Figueiredo-Pereira ME, Fimia GM, Fingar DC, Finkbeiner S, Finkel T, Finley KD, Fiorito F, Fisher EA, Fisher PB, Flajolet M, Florez-McClure ML, Florio S, Fon EA, Fornai F, Fortunato F, Fotedar R, Fowler DH, Fox HS, Franco R, Frankel LB, Fransen M, Fueyo J, Fujii J, Fujisaki K, Fujita E, Fukuda M, Furukawa RH, Gaestel M, Gailly P, Gajewska M, Galliot B, Galy V, Ganesh S, Ganetzky B, Ganley IG, Gao FB, Gao GF, Gao J, Garcia L, Garcia-Manero G, Garcia-Marcos M, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012 Apr; 8(4):445-544. PMID: 22966490; PMCID: PMC3404883.
      Citations: 1751     Fields:    Translation:HumansAnimals
    167. Walker GV, Li J, Mahajan A, McAleer MF, de Groot JF, Azeem SS, Brown PD. Decreasing radiation therapy utilization in adult patients with glioblastoma multiforme: a population-based analysis. Cancer. 2012 Sep 15; 118(18):4538-44. PMID: 22359097.
      Citations: 6     Fields:    Translation:Humans
    168. Giglio P, Dhamne M, Hess KR, Gilbert MR, Groves MD, Levin VA, Kang SL, Ictech SE, Liu V, Colman H, Conrad CA, Loghin M, de Groot J, Yung WK, Puduvalli VK. Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma. Cancer. 2012 Jul 15; 118(14):3599-606. PMID: 22086614.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    169. de Groot JF. High-dose antiangiogenic therapy for glioblastoma: less may be more? Clin Cancer Res. 2011 Oct 01; 17(19):6109-11. PMID: 21852387.
      Citations: 12     Fields:    Translation:HumansAnimals
    170. Wen PY, Schiff D, Cloughesy TF, Reardon DA, Batchelor TT, Chabner BA, Flaherty K, de Groot JF, Gilbert MR, Galanis E, Chang SM, Schwartz GK, Peereboom D, Mehta MP, Yung WK, Grossman SA, Prados MD, DeAngelis LM. It is time to include patients with brain tumors in phase I trials in oncology. J Clin Oncol. 2011 Aug 20; 29(24):3211-3. PMID: 21768451; PMCID: PMC4836609.
      Citations: 9     Fields:    Translation:Humans
    171. de Groot JF, Piao Y, Tran H, Gilbert M, Wu HK, Liu J, Bekele BN, Cloughesy T, Mehta M, Robins HI, Lassman A, DeAngelis L, Camphausen K, Chen A, Yung WK, Prados M, Wen PY, Heymach JV. Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept. Clin Cancer Res. 2011 Jul 15; 17(14):4872-81. PMID: 21632852; PMCID: PMC3139700.
      Citations: 32     Fields:    Translation:HumansCellsCTClinical Trials
    172. de Groot JF, Lamborn KR, Chang SM, Gilbert MR, Cloughesy TF, Aldape K, Yao J, Jackson EF, Lieberman F, Robins HI, Mehta MP, Lassman AB, Deangelis LM, Yung WK, Chen A, Prados MD, Wen PY. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol. 2011 Jul 01; 29(19):2689-95. PMID: 21606416; PMCID: PMC3139373.
      Citations: 83     Fields:    Translation:HumansCTClinical Trials
    173. de Groot JF, Sulman EP, Aldape KD. Multigene sets for clinical application in glioma. J Natl Compr Canc Netw. 2011 Apr; 9(4):449-56; quiz 457. PMID: 21464148.
      Citations: 1     Fields:    Translation:HumansCells
    174. Reardon DA, Galanis E, DeGroot JF, Cloughesy TF, Wefel JS, Lamborn KR, Lassman AB, Gilbert MR, Sampson JH, Wick W, Chamberlain MC, Macdonald DR, Mehta MP, Vogelbaum MA, Chang SM, Van den Bent MJ, Wen PY. Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol. 2011 Mar; 13(3):353-61. PMID: 21310734; PMCID: PMC3064608.
      Citations: 52     Fields:    Translation:Humans
    175. de Groot J, Sontheimer H. Glutamate and the biology of gliomas. Glia. 2011 Aug; 59(8):1181-9. PMID: 21192095; PMCID: PMC3107875.
      Citations: 119     Fields:    Translation:HumansAnimalsCells
    176. Ahluwalia MS, de Groot J, Liu WM, Gladson CL. Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies. Cancer Lett. 2010 Dec 08; 298(2):139-49. PMID: 20947248; PMCID: PMC3212431.
      Citations: 66     Fields:    Translation:HumansCells
    177. Gilbert MR, Gonzalez J, Hunter K, Hess K, Giglio P, Chang E, Puduvalli V, Groves MD, Colman H, Conrad C, Levin V, Woo S, Mahajan A, de Groot J, Yung WK. A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. Neuro Oncol. 2010 Nov; 12(11):1167-72. PMID: 20729242; PMCID: PMC3098026.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    178. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010 Apr 10; 28(11):1963-72. PMID: 20231676.
      Citations: 1517     Fields:    Translation:Humans
    179. de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y, Conrad CA. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol. 2010 Mar; 12(3):233-42. PMID: 20167811; PMCID: PMC2940588.
      Citations: 258     Fields:    Translation:HumansAnimals
    180. Lucio-Eterovic AK, Piao Y, de Groot JF. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res. 2009 Jul 15; 15(14):4589-99. PMID: 19567589.
      Citations: 105     Fields:    Translation:HumansAnimalsCells
    181. de Groot J, Milano V. Improving the prognosis for patients with glioblastoma: the rationale for targeting Src. J Neurooncol. 2009 Nov; 95(2):151-163. PMID: 19436954.
      Citations: 24     Fields:    Translation:Humans
    182. Vaillant B, Kuo SH, de Groot J. Emerging subspecialties in neurology: neuro-oncology: a developing subspecialty with many opportunities. Neurology. 2009 Mar 17; 72(11):e51-3. PMID: 19289732.
      Citations: 1     Fields:    Translation:Humans
    183. Walker JG, Kadia T, Brown L, Juneja HS, de Groot JF. Dapsone induced methemoglobinemia in a patient with glioblastoma. J Neurooncol. 2009 Aug; 94(1):149-52. PMID: 19219404; PMCID: PMC4438990.
      Citations: 5     Fields:    Translation:Humans
    184. Milano V, Piao Y, LaFortune T, de Groot J. Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma. Mol Cancer Ther. 2009 Feb; 8(2):394-406. PMID: 19190119.
      Citations: 65     Fields:    Translation:HumansCells
    185. Kuo SH, Debnam JM, Fuller GN, de Groot J. Wernicke's encephalopathy: an underrecognized and reversible cause of confusional state in cancer patients. Oncology. 2009; 76(1):10-8. PMID: 19018150.
      Citations: 19     Fields:    Translation:Humans
    186. Gonzalez J, de Groot J. Combination therapy for malignant glioma based on PTEN status. Expert Rev Anticancer Ther. 2008 Nov; 8(11):1767-79. PMID: 18983237.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    187. Piao Y, Lu L, de Groot J. AMPA receptors promote perivascular glioma invasion via beta1 integrin-dependent adhesion to the extracellular matrix. Neuro Oncol. 2009 Jun; 11(3):260-73. PMID: 18957620; PMCID: PMC2718970.
      Citations: 46     Fields:    Translation:HumansAnimalsCells
    188. de Groot JF, Yung WK. Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas. Cancer J. 2008 Sep-Oct; 14(5):279-85. PMID: 18836331.
      Citations: 21     Fields:    Translation:Humans
    189. Gomez-Manzano C, Holash J, Fueyo J, Xu J, Conrad CA, Aldape KD, de Groot JF, Bekele BN, Yung WK. VEGF Trap induces antiglioma effect at different stages of disease. Neuro Oncol. 2008 Dec; 10(6):940-5. PMID: 18708344; PMCID: PMC2719008.
      Citations: 43     Fields:    Translation:HumansAnimals
    190. de Groot JF, Gilbert MR, Aldape K, Hess KR, Hanna TA, Ictech S, Groves MD, Conrad C, Colman H, Puduvalli VK, Levin V, Yung WK. Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. J Neurooncol. 2008 Oct; 90(1):89-97. PMID: 18581057; PMCID: PMC6059769.
      Citations: 45     Fields:    Translation:HumansCTClinical Trials
    191. de Groot JF, Piao Y, Lu L, Fuller GN, Yung WK. Knockdown of GluR1 expression by RNA interference inhibits glioma proliferation. J Neurooncol. 2008 Jun; 88(2):121-33. PMID: 18317690.
      Citations: 37     Fields:    Translation:HumansAnimalsCells
    192. Puduvalli VK, Giglio P, Groves MD, Hess KR, Gilbert MR, Mahankali S, Jackson EF, Levin VA, Conrad CA, Hsu SH, Colman H, de Groot JF, Ritterhouse MG, Ictech SE, Yung WK. Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. Neuro Oncol. 2008 Apr; 10(2):216-22. PMID: 18314417; PMCID: PMC2613824.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    193. de Groot JF, Gilbert MR. New molecular targets in malignant gliomas. Curr Opin Neurol. 2007 Dec; 20(6):712-8. PMID: 17992095.
      Citations: 17     Fields:    Translation:Humans
    194. Liu TJ, LaFortune T, Honda T, Ohmori O, Hatakeyama S, Meyer T, Jackson D, de Groot J, Yung WK. Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol Cancer Ther. 2007 Apr; 6(4):1357-67. PMID: 17431114.
      Citations: 86     Fields:    Translation:AnimalsCells
    195. Koul D, Shen R, Bergh S, Sheng X, Shishodia S, Lafortune TA, Lu Y, de Groot JF, Mills GB, Yung WK. Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma. Mol Cancer Ther. 2006 Mar; 5(3):637-44. PMID: 16546978.
      Citations: 38     Fields:    Translation:HumansCells
    196. Koul D, Shen R, Bergh S, Lu Y, de Groot JF, Liu TJ, Mills GB, Yung WK. Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma. Mol Cancer Ther. 2005 Nov; 4(11):1681-8. PMID: 16275989.
      Citations: 35     Fields:    Translation:HumansCells
    197. de Groot JF, Liu TJ, Fuller G, Yung WK. The excitatory amino acid transporter-2 induces apoptosis and decreases glioma growth in vitro and in vivo. Cancer Res. 2005 Mar 01; 65(5):1934-40. PMID: 15753393.
      Citations: 42     Fields:    Translation:HumansAnimalsCells
    198. Benjamin RK, Hochberg FH, Fox E, Bungay PM, Elmquist WF, Stewart CF, Gallo JM, Collins JM, Pelletier RP, de Groot JF, Hickner RC, Cavus I, Grossman SA, Colvin OM. Review of microdialysis in brain tumors, from concept to application: first annual Carolyn Frye-Halloran symposium. Neuro Oncol. 2004 Jan; 6(1):65-74. PMID: 14769143; PMCID: PMC1871970.
      Citations: 14     Fields:    Translation:HumansAnimals
    199. deGroot J, Zhou S, Carlton SM. Peripheral glutamate release in the hindpaw following low and high intensity sciatic stimulation. Neuroreport. 2000 Feb 28; 11(3):497-502. PMID: 10718302.
      Citations: 58     Fields:    Translation:AnimalsCells
    200. deGroot JF, Coggeshall RE, Carlton SM. The reorganization of mu opioid receptors in the rat dorsal horn following peripheral axotomy. Neurosci Lett. 1997 Sep 19; 233(2-3):113-6. PMID: 9350845.
      Citations: 9     Fields:    Translation:Animals
    201. B lymphoblastic leukemia/lymphoma presenting as seventh cranial nerve palsy. Neurology: Clinical Practice. 3:532-534.
    202. Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma. Journal of Neuro-Oncology. 1-8.
    203. Reply to J.W. Locasale et al. Journal of Clinical Oncology. 30:338-339.
    204. Periostin (POSTN) regulates tumor resistance to antiangiogenic therapy in glioma models. Molecular Cancer Therapeutics. 15:2187-2197.
    205. Prioritization schema for immunotherapy clinical trials in glioblastoma. OncoImmunology.
    206. Interferon-regulatory factor-1 (IRF1) regulates bevacizumab induced autophagy. Oncotarget. 6:31479-31492.
    207. Cell Signaling Pathways in Brain Tumors. Topics in Magnetic Resonance Imaging.
    208. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models. Neuro-Oncology. 18:1230-1241.
    209. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma. Neuro-Oncology. 18:557-564.
    210. VEGF manipulation in glioblastoma. ONCOLOGY (United States). 29:720-727.
    211. Personalized medicine and targeted therapy of gliomas. 878-899.
    212. A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients. Journal of Neuro-Oncology.
    213. Cdc2-like kinase 2 is a key regulator of the cell cycle via FOXO3a/p27 in glioblastoma. Oncotarget. 7:26793-26805.
    214. Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials. Journal of Clinical Oncology. 33:2753-2762.
    215. Effect of vascularization on glioma tumor growth. 237-259.
    216. Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma. Journal of Neuro-Oncology. 1-9.
    217. A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma. Journal of Neuro-Oncology. 1-8.
    218. Adult medulloblastoma, from spongioblastoma cerebelli to the present day. ONCOLOGY (United States). 26.
    219. Using CSF as an internal quality assurance tool in diffusion tensor imaging studies of brain tumor.
    220. A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma. Journal of Neuro-Oncology. 126:309-316.
    221. Molecular subtypes of glioblastoma are relevant to lower grade glioma. PLoS One. 9.
    222. Immune checkpoint blockade as a potential therapeutic target. Neuro-Oncology. 18:1357-1366.
    223. Erratum. Journal of Neuro-Oncology. 113:151.
    224. Melanoma central nervous system metastases. Pigment Cell and Melanoma Research. 29:627-642.
    225. Erratum. Neuro-Oncology. 6:172.
    226. Toward precision medicine in glioblastoma. Neuro-Oncology. 17:1051-1063.
    227. Targeted therapeutic strategies for relapsed disease. 29-40.
    DE GROOT's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (534)
    Co-Authors (145)
    Similar People (60)
    Same Department Expand Description